Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30492208 | 1.00 | SQOR (0.48) | SQORMAPTALDH1A1KDM4EHPGD | |
| SCHEMBL751950 | 0.81 | LMNA (0.41) | MAPTALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL30046816 | 0.81 | LMNA (0.41) | MAPTALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL6637131 | 0.78 | ALDH1A1 (0.52) | MAPTALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL2007502 | 0.78 | LMNA (0.49) | MAPTALDH1A1KDM4ELMNANPC1 | |
| SCHEMBL2221831 | 0.75 | KDM4E (0.46) | MAPTALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL2686237 | 0.74 | PIK3CB (0.43) | MAPTALDH1A1LMNAMAPK1L3MBTL1 | |
| SCHEMBL2686241 | 0.74 | PIK3CB (0.43) | MAPTALDH1A1LMNAMAPK1L3MBTL1 | |
| SCHEMBL11458373 | 0.74 | AURKA (0.44) | MAPTALDH1A1TP53LMNAMAPK1 | |
| SCHEMBL14665458 | 0.73 | DGAT1 (0.43) | MAPTALDH1A1KDM4ETP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466839-B2 | Allosteric AKT inhibitors for use in the treatment of Hereditary Hemorrhagic Telangiectasia | VADERIS THERAPEUTICS AG (CH) | 2025-11-11 | — | — | US | disclosed |
| US-20240092801-A1 | ALLOSTERIC AKT INHIBITORS FOR USE IN THE TREATMENT OF HEREDITARY HEMORRHAGIC TELANGIECTASIA | VADERIS THERAPEUTICS AG (CH) | 2024-03-21 | — | — | US | disclosed |
| EP-4221713-A1 | ALLOSTERIC AKT INHIBITORS FOR USE IN THE TREATMENT OF HEREDITARY HEMORRHAGIC TELANGIECTASIA | Vaderis Therapeutics AG (CH) | 2023-08-09 | — | — | EP | disclosed |
| CN-116419924-A | Allosteric AKT inhibitors for the treatment of hereditary hemorrhagic telangiectasia | 韦德里斯治疗股份公司 | 2023-07-11 | — | — | CN | disclosed |
| WO-2022069552-A1 | ALLOSTERIC AKT INHIBITORS FOR USE IN THE TREATMENT OF HEREDITARY HEMORRHAGIC TELANGIECTASIA | VADERIS THERAPEUTICS AG (CH) | 2022-04-07 | — | — | WO | disclosed |
| US-9221838-B2 | Inhibitors of AKT activity | ALMAC DISCOVERY LIMITED (IE) | 2015-12-29 | — | — | US | disclosed |
| EP-2516435-B1 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LTD (GB) | 2014-08-06 | — | — | EP | disclosed |
| US-20130116243-A1 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| EP-2516435-A1 | INHIBITORS OF AKT ACTIVITY | Almac Discovery Limited (GB) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011077098-A9 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LIMITED (GB) | 2012-04-19 | — | — | WO | disclosed |
| WO-2011077098-A1 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466839-B2 | Allosteric AKT inhibitors for use in the treatment of Hereditary Hemorrhagic Telangiectasia | AKT1, PIK3CA, AKT3 | SQOR 4090/4885MAPT 2011/4885ALDH1A1 4479/4885 |
| US-20130116243-A1 | INHIBITORS OF AKT ACTIVITY | AKT2, AKT1, AKT3 | SQOR 3227/4885MAPT 1269/4885ALDH1A1 4294/4885 |
| US-20240092801-A1 | ALLOSTERIC AKT INHIBITORS FOR USE IN THE TREATMENT OF HEREDITARY HEMORRHAGIC TELANGIECTASIA | AKT1, PIK3CA, AKT3 | SQOR 4090/4885MAPT 2011/4885ALDH1A1 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.